

## Care Source NETWORK Notification

**Notice Date:** December 1, 2022

CareSource North Carolina Co.® Providers To:

From: **CareSource** 

Subject: **Avalon Laboratory Policy Updates** 

## **Summary**

CareSource North Carolina Co. has partnered with Avalon Healthcare Solutions for laboratory benefits management (LBM), including routine testing management (RTM), a post-service pre-payment clinical claim editing program for routine lab testing for our CareSource North Carolina Co. members.

Our goal is to keep you informed with timely information about our laboratory benefits management (LBM), including routine testing management (RTM) updates and changes. The RTM program is based on ensuring compliance with the lab policies. As changes occur and as needs arise, we issue network notifications to our providers.

This notification is intended to provide you notification of changes to the policies listed below. The policies appear on Avalon's website upon their effective dates.

## **Policies**

Policy Name	Plans	Effective Date
F2019: Flow Cytometry – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2002: Cervical Cancer Screening – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
G2005: Vitamin D Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2006: Hemoglobin A1c – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2007: Prostate Biopsies – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2008: Prostate Specific Antigen PSA Testing – Effective Date: 01- 01-2023		01/01/2023
G2009: Preventive Screening in	North Carolina Marketplace	01/01/2023

Adults – Effective Date: 01-01- 2023 G2011: Diagnostic Testing of Iron		
Homeostasis and Metabolism – Effective Date: 01-01-2023		
G2013: Testosterone Testing– Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2014: Vitamin B12 and Methylmalonic Acid Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2022: ANA/ENA Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2031: Allergen Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2035: Prenatal Screening (nongenetic) – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
G2036: Hepatitis C – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2042: Pediatric Preventive Screening – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
G2043: Celiac Disease – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2044: Helicobacter pylori Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2045: Thyroid Disease Testing  – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2048: Biochemical Markers of Alzheimer Disease and Dementia – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2050: Cardiovascular Disease Risk Assessment – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2051: Bone Turnover Markers Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2055: Prenatal Screening for Fetal Aneuploidy – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2056: Diagnosis of Idiopathic Environmental Intolerance – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2059: Epithelial Cell Cytology in	North Carolina Marketplace	01/01/2023

Breast Cancer Risk Assessment  – Effective Date: 01-01-2023		
G2060: Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2061: Fecal Calprotectin Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2063: Testing for Diagnosis of Active or Latent Tuberculosis – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2098: Immune Cell Function Assay – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2099: Intracellular Micronutrient Analysis – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2100: In Vitro Chemoresistance and Chemosensitivity Assays – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2105: Immunopharmacologic Monitoring of Therapeutic Serum Antibodies – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
G2107: Measurement of Thromboxane Metabolites for ASA Resistance – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2110: Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2113: Oral Screening Lesion Identification Systems and Genetic Screening – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2115: Metabolite Markers of Thiopurines Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2119: Diagnostic Testing of Influenza – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2120: Salivary Hormone Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023

G2121: Lab Testing for the Diagnosis of IBD – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
	Nowth Carolina Markatalaga	01/01/2023
G2123: Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases – Effective Date: 01-01-2023		01/01/2023
G2124: Serum Tumor Markers for Malignancies – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2125: Urinary Tumor Markers For Bladder Cancer – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2127: Vectra DA Blood Test for Rheumatoid Arthritis – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2130: ST2 Assay for Chronic Heart Failure – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2133: ZIKA Virus Risk Assessment – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
G2138: Evaluation of Dry Eyes – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2143: Lyme Disease – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2149: Pathogen Panel Testing  – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2150: Cardiac Biomarkers for Myocardial Infarction – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2153: Pancreatic Enzyme Testing for Acute Pancreatitis – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2154: Folate Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2155: General Inflammation Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2156: Urine Culture Testing for Bacteria – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
G2157: Diagnostic Testing Of Common Sexually Transmitted Infections – Effective Date: 01-	North Carolina Marketplace	01/01/2023

01-2023		
G2158: Testing for Mosquito- or Tick-Related Infections – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2159: B-Hemolytic Streptococcus Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2164: Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
G2173: Gamma-glutamyl Transferase – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
G2174: Coronavirus Testing in the Outpatient Setting – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
M2041: Venous and Arterial Thrombosis Risk Testing – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
M2057: Diagnosis of Vaginitis including Multi-target PCR Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
M2058: Genetic Testing for Adolescent Idiopathic Scoliosis – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
M2068: Testing for Alpha-1 Antitrypsin Deficiency – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
M2093: HIV Genotyping and Phenotyping – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
M2097: Identification of Microorganisms using Nucleic Acid Probes – Effective Date: 01- 01-2023	North Carolina Marketplace	01/01/2023
M2112: Nerve Fiber Density Testing – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
M2116: Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection – Effective Date: 01-01- 2023	North Carolina Marketplace	01/01/2023
M2141: Testing of Homocysteine Metabolism-Related Conditions – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023

M2172: Onychomycosis Testing  – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
M2176: Testing for Autism Spectrum Disorder and Developmental Delay – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
P2018: Immunohistochemistry – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
R2162: Laboratory Procedures Reimbursement Policy – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023
T2015: Prescription Medication and Illicit Drug Testing in the Outpatient Setting – Effective Date: 01-01-2023	North Carolina Marketplace	01/01/2023

## **Trial Claim Advice Tool**

Providers may use the Trial Claim Advice tool to review claims with laboratory services for adherence and consistency with CareSource laboratory policies. This is a simulation tool and does not guarantee approval or reimbursement of claims. You can access the Trial Claim Advice Tool on the CareSource <u>Provider Portal</u>.

NC-EXC-P-1695762

Qualified Health Plans offered in North Carolina by CareSource North Carolina Co., d/b/a CareSource

**PARTNER** with **PURPOSE**